Genmab — Juli 2017
-
OK
-
-
God eftermiddag. Der er nok at glæde sig til i den kommende tid: Q3-2017: Darzalex ph III ALCYONE frontline MM data with Velcade
H2 2017: ESMO Congress – 8-12 September
H2 2017: Ph II data for Tisotumab Vedotin (likely at ESMO)
H2 2017: Darzalex Ph II data in high-risk smouldering myeloma
(CENTAURUS study) likely in Q4 (ASH)
H2 2017: Darzalex ph II data in multiple myeloma with Celgene’s
durvalumab
H1 2018: Darzalex ph III MAIA frontline MM data with Revlimid -
Since you mentioned durvalumab, had news today: IMFINZI
(durvalumab) granted Breakthrough Therapy Designation by US FDA for patients with locally advanced unresectable non-small cell lung cancer https://www.astrazeneca-us.com/media/press-releases/2017/imfinzi-durvalumab-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-locally-advanced-unresectable-non-small-cell-lung-cancer-07312017.html -
Mht snakken ca kl 10.00 - Novod forventer Dara passerer 5,3 mia i salg 2021 alene i MM. CITI at knap 6 mia passeres i 2021 også i MM. CITI siger totalmarked i 2025 for US (MM) alene vil være 28 mia $ og at verdensmarkedet umiddelbart (normalt) bliver det dobbelte!! (46 mia). Så kan man jo tænke lidt på markedsandel for DARA. CITI regner med 11 mia i topsalg for Dara, men der er mange faktorer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind